Amgen, Inc. (NASDAQ:AMGN) EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $185.62, for a total value of $283,070.50. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Shares of Amgen, Inc. (NASDAQ AMGN) opened at $187.59 on Friday. The company has a current ratio of 6.07, a quick ratio of 5.72 and a debt-to-equity ratio of 1.05. Amgen, Inc. has a twelve month low of $150.38 and a twelve month high of $191.10. The company has a market capitalization of $136,478.44, a PE ratio of 16.98, a P/E/G ratio of 2.75 and a beta of 1.36.

Amgen (NASDAQ:AMGN) last released its earnings results on Wednesday, October 25th. The medical research company reported $3.27 EPS for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The firm had revenue of $5.77 billion during the quarter, compared to the consensus estimate of $5.75 billion. During the same quarter in the previous year, the company posted $3.02 earnings per share. The company’s revenue was down .7% compared to the same quarter last year. analysts expect that Amgen, Inc. will post 12.71 EPS for the current fiscal year.

Amgen announced that its board has approved a share buyback program on Wednesday, October 25th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical research company to buy shares of its stock through open market purchases. Shares buyback programs are usually a sign that the company’s leadership believes its stock is undervalued.

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 8th. Investors of record on Thursday, February 15th will be issued a dividend of $1.32 per share. This is an increase from Amgen’s previous quarterly dividend of $1.15. The ex-dividend date is Wednesday, February 14th. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.81%. Amgen’s payout ratio is 41.63%.

Several institutional investors have recently added to or reduced their stakes in the stock. Syntal Capital Partners LLC acquired a new position in Amgen in the fourth quarter valued at approximately $210,000. Butensky & Cohen Financial Security Inc. lifted its holdings in Amgen by 4.5% in the fourth quarter. Butensky & Cohen Financial Security Inc. now owns 7,435 shares of the medical research company’s stock valued at $1,293,000 after acquiring an additional 320 shares during the period. Fox Run Management L.L.C. lifted its holdings in Amgen by 57.7% in the fourth quarter. Fox Run Management L.L.C. now owns 4,257 shares of the medical research company’s stock valued at $740,000 after acquiring an additional 1,557 shares during the period. Cardinal Capital Management Inc. lifted its holdings in Amgen by 1,394.8% in the fourth quarter. Cardinal Capital Management Inc. now owns 60,540 shares of the medical research company’s stock valued at $10,528,000 after acquiring an additional 56,490 shares during the period. Finally, Westpac Banking Corp lifted its holdings in Amgen by 9.1% in the fourth quarter. Westpac Banking Corp now owns 88,303 shares of the medical research company’s stock valued at $15,356,000 after acquiring an additional 7,363 shares during the period. 78.48% of the stock is owned by hedge funds and other institutional investors.

Several research firms have recently weighed in on AMGN. BidaskClub upgraded Amgen from a “sell” rating to a “hold” rating in a research report on Thursday. Oppenheimer set a $205.00 target price on Amgen and gave the stock a “buy” rating in a research report on Friday, January 5th. BMO Capital Markets reiterated a “hold” rating and set a $199.00 target price on shares of Amgen in a research report on Monday, September 25th. Vetr downgraded Amgen from a “buy” rating to a “hold” rating and set a $184.25 target price for the company. in a research report on Wednesday, January 3rd. Finally, Credit Suisse Group restated a “neutral” rating and issued a $186.00 price objective (up from $177.00) on shares of Amgen in a report on Friday, September 29th. Fifteen investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $190.15.

COPYRIGHT VIOLATION NOTICE: “Sean E. Harper Sells 1,525 Shares of Amgen, Inc. (AMGN) Stock” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/sean-e-harper-sells-1525-shares-of-amgen-inc-amgn-stock/1813453.html.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.